Compare Palantir Technologies Inc (PLTR) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Tempus AI — how do they compare? Palantir Technologies Inc trades at $200.57 (market cap $466.48B), while Tempus AI trades at $70.19 (market cap $12.77B). The key difference: Palantir Technologies Inc is far larger — about 36.5× Tempus AI's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and Tempus AI for 22 Days on average.
| PLTR | TEM | |
|---|---|---|
Market Cap | $466.48B | $12.77B |
Volume | 15,675,589 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $207.18 | $99.28 |
52-Week Low | $107.27 | $41.55 |
Typical Hold Time | 78 Days | 22 Days |
Enterprise Value | $457.28B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $194.04, up 1.02% with a bullish technical outlook and strong fundamental momentum. The stock shows robust revenue growth of 56.2% in 2025, reaching $4.48 billion, with net income surging to $1.63 billion. Recent partnerships with Armada for sovereign AI infrastructure and consistent earnings beats highlight operational strength, though valuation metrics remain elevated with a P/E of 165.91.
The outlook remains positive with analyst consensus at Buy (53.84%) and a $191.69 price target. Key opportunities include AI platform expansion and commercial customer growth to 870, while risks involve high valuation sensitivity and competitive pressures. The stock trades near recent highs with support at $191 and resistance at $195.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
